CA2494975A1 - Substituted 1,4-pyrazine derivatives - Google Patents

Substituted 1,4-pyrazine derivatives Download PDF

Info

Publication number
CA2494975A1
CA2494975A1 CA002494975A CA2494975A CA2494975A1 CA 2494975 A1 CA2494975 A1 CA 2494975A1 CA 002494975 A CA002494975 A CA 002494975A CA 2494975 A CA2494975 A CA 2494975A CA 2494975 A1 CA2494975 A1 CA 2494975A1
Authority
CA
Canada
Prior art keywords
alkyl
substituted
nr5r5
cycloalkyl
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002494975A
Other languages
English (en)
French (fr)
Inventor
Jeffrey W. Corbett
Jian-Min Fu
Michael D. Ennis
Kristine E. Frank
Robert L. Hoffman
Patrick R. Verhoest
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2494975A1 publication Critical patent/CA2494975A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA002494975A 2002-09-12 2003-08-27 Substituted 1,4-pyrazine derivatives Abandoned CA2494975A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41026102P 2002-09-12 2002-09-12
US60/410,261 2002-09-12
PCT/US2003/024805 WO2004024719A1 (en) 2002-09-12 2003-08-27 Substituted 1,4-pyrazine derivatives

Publications (1)

Publication Number Publication Date
CA2494975A1 true CA2494975A1 (en) 2004-03-25

Family

ID=31994096

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002494975A Abandoned CA2494975A1 (en) 2002-09-12 2003-08-27 Substituted 1,4-pyrazine derivatives

Country Status (10)

Country Link
US (1) US20040116444A1 (cg-RX-API-DMAC10.html)
EP (1) EP1539736A1 (cg-RX-API-DMAC10.html)
JP (1) JP2006506350A (cg-RX-API-DMAC10.html)
AR (1) AR041125A1 (cg-RX-API-DMAC10.html)
AU (1) AU2003269949A1 (cg-RX-API-DMAC10.html)
BR (1) BR0314139A (cg-RX-API-DMAC10.html)
CA (1) CA2494975A1 (cg-RX-API-DMAC10.html)
MX (1) MXPA05002418A (cg-RX-API-DMAC10.html)
TW (1) TW200503717A (cg-RX-API-DMAC10.html)
WO (1) WO2004024719A1 (cg-RX-API-DMAC10.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05012082A (es) * 2003-05-09 2006-02-22 Pharmacia & Upjohn Co Llc Compuestos como antagonistas del receptor crf1.
US20060211710A1 (en) * 2005-03-17 2006-09-21 Pfizer Inc Substituted aryl 1,4-pyrazine derivatives
IL311645B2 (en) * 2016-07-12 2025-11-01 Revolution Medicines Inc 2,5- disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines asallosteric shp2 inhibitors
CN110446709B (zh) 2017-01-23 2023-09-12 锐新医药公司 作为变构shp2抑制剂的二环化合物
CA3051054A1 (en) 2017-01-23 2018-07-26 Revolution Medicines, Inc. Pyridine compounds as allosteric shp2 inhibitors
TWI852912B (zh) 2017-09-07 2024-08-21 美商銳新醫藥公司 Shp2抑制劑組合物以及治療癌症的方法
BR112020007058A2 (pt) 2017-10-12 2020-10-06 Revolution Medicines, Inc. compostos de piridina, pirazina, e triazina como inibidores de shp2 alostéricos
BR112020009757A2 (pt) 2017-12-15 2020-11-03 Revolution Medicines, Inc. compostos policíclicos como inibidores alostéricos de shp2
PL3788049T3 (pl) 2018-05-01 2023-06-19 Revolution Medicines, Inc. Połączone z C40, C28 i C32 analogi rapamycyny jako inhibitory mTOR
EP3788050B1 (en) 2018-05-01 2024-08-28 Revolution Medicines, Inc. C26-linked rapamycin analogs as mtor inhibitors
EP4531859A4 (en) 2022-05-25 2026-05-27 Revolution Medicines Inc CANCER TREATMENT METHODS USING AN MTOR INHIBITOR

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4270297A (en) * 1996-09-16 1998-04-02 Du Pont Pharmaceuticals Company Pyrazinones and triazinones and their derivatives thereof
PA8467401A1 (es) * 1998-02-17 2000-09-29 Pfizer Prod Inc Procedimiento para tratar la insuficiencia cardiaca
IL139197A0 (en) * 1999-10-29 2001-11-25 Pfizer Prod Inc Use of corticotropin releasing factor antagonists and related compositions
ATE307121T1 (de) * 2000-02-16 2005-11-15 Neurogen Corp Substituierte arylpyrazine

Also Published As

Publication number Publication date
US20040116444A1 (en) 2004-06-17
AR041125A1 (es) 2005-05-04
TW200503717A (en) 2005-02-01
MXPA05002418A (es) 2005-05-27
BR0314139A (pt) 2005-07-12
AU2003269949A1 (en) 2004-04-30
WO2004024719A1 (en) 2004-03-25
JP2006506350A (ja) 2006-02-23
EP1539736A1 (en) 2005-06-15

Similar Documents

Publication Publication Date Title
EP0927171B1 (en) Pyrazinones and triazinones and their derivatives thereof
US20080107608A1 (en) 5-Substituted-2-Arylpyridines
KR20030031886A (ko) 치환된 아릴피라진
SK6142000A3 (en) HETEROARYL DIAZACYCLOALKANES AS CHOLINERGIC LIGANDS AT NICOTINICì (54) ACETYLCHOLINE RECEPTORS
CA2731919A1 (en) New compounds
US20040116444A1 (en) Substituted 1,4-pyrazine derivatives
US7087617B2 (en) Substituted pyrimidine derivatives
US7250418B2 (en) Compounds as CRF1 receptor antagonists
US20040053941A1 (en) Substituted pyrazine derivatives
CA2601600C (en) Substituted aryl 1,4-pyrazine derivatives
JP2008503444A (ja) Crf受容体アンタゴニスト、その調製法、その医薬組成物およびその使用
EP1620428A1 (en) Substituted pyrimidinones and pyrimidinthiones as crf antagonists
WO2001068614A2 (en) 5-substituted arylpyrimidines
CA2523072A1 (en) Pyrrolo (1,2-b) pyridazine compounds and their use as crf-1 receptor antagonists
US7074791B2 (en) Pyrrolo[1,2-b]pyridazine compounds and their uses
WO2004046136A9 (en) Pyrazine compounds as crf modulators
EP3992188A1 (en) Difluoromethyl-pyridin-2-yl triazoles
EP3971179A1 (en) Difluoromethyl-pyridin-2-yl triazoles
EP1615929A1 (en) Pyrrolo [1,2-b] pyridazine compounds and their uses

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued